col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


77 Results       Page 1

 [1] 
American Society for Microbiology: Antimicrobial Agents and Chemotherapy
  original article Date Title Authors   All Authors
1 [GO] 2024―Mar―27 Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19 Lindsay E. Clegg, Oleg Stepanov, Henning Schmidt, Weifeng Tang, Huixia Zhang, Chris Webber, et al. (+4)
2 [GO] 2024―Mar―12 Two-way pharmacodynamic modeling of drug combinations and its application to pairs of repurposed Ebola and SARS-CoV-2 agents Shuang Xu, Shadisadat Esmaeili, E. Fabian Cardozo-Ojeda, Ashish Goyal, Judith M. White, Stephen J. Polyak, et al. (+2)
3 [GO] 2024―Mar―06 BPR3P0128, a non-nucleoside RNA-dependent RNA polymerase inhibitor, inhibits SARS-CoV-2 variants of concern and exerts synergistic antiviral activity in combination with remdesivir Wen-Fang Tang, Yu-Hsiu Chang, Cheng-Chin Lin, Jia-Rong Jheng, Chung-Fan Hsieh, Yuan-Fan Chin, et al. (+24)
4 [GO] 2024―Feb―06 Repurposing screen identifies novel candidates for broad-spectrum coronavirus antivirals and druggable host targets Sibylle Haid, Alina Matthaei, Melina Winkler, Svenja M. Sake, Antonia P. Gunesch, Vanessa Milke, et al. (+17)
5 [GO] 2024―Jan―31 Manidipine is not a potential inhibitor against SARS-CoV-2 main protease Rui Zhang, Jiahao Zhou, Haohao Yan, Xiaoping Liu, Chao Shang, Yunyu Chen, Miguel Angel Martinez
6 [GO] 2024―Jan―30 Effectiveness and safety of nirmatrelvir-ritonavir in kidney transplant recipients with severe kidney dysfunction infected with COVID-19 Hui Yang, Xin Yu, Wenjing Hou, Xiangduan Liu, Jiaojiao Chen, Ying Zhang, et al. (+6)
7 [GO] 2023―Dec―15 Phase I study, and dosing regimen selection for a pivotal COVID-19 trial of GST-HG171 Hong Zhang, Jing Zhou, Hong Chen, John Mao, Yanan Tang, Wenhao Yan, et al. (+8)
8 [GO] 2023―Dec―04 Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance Julie M. Strizki, John M. Gaspar, John A. Howe, Beth Hutchins, Hiroshi Mohri, Manoj S. Nair, et al. (+5)
9 [GO] 2023―Oct―06 Evaluation of in vitro antiviral activity of SARS-CoV-2 M pro inhibitor pomotrelvir and cross-resistance to nirmatrelvir resistance substitutions Xiao Tong, Walter Keung, Lee D. Arnold, Laura J. Stevens, Andrea J. Pruijssers, Seunghyi Kook, et al. (+4)
10 [GO] 2023―Jun―06 Frequent Emergence of Resistance Mutations Following Complex Intra-Host Genomic Dynamics in SARS-CoV-2 Patients Receiving Sotrovimab Rosalía Palomino-Cabrera, Francisco Tejerina, Andrea Molero-Salinas, María Ferris, Cristina Veintimilla, Pilar Catalán, et al. (+61)
11 [GO] 2023―Mar―28 Inhibition of Human Coronaviruses by Combinations of Host-Targeted and Direct-Acting Antivirals Patricia de León, Rodrigo Cañas-Arranz, María José Bustos, Margarita Sáiz, Francisco Sobrino
12 [GO] 2023―Jan―05 Atypical Mutational Spectrum of SARS-CoV-2 Replicating in the Presence of Ribavirin Pilar Somovilla, Carlos García-Crespo, Brenda Martínez-González, María Eugenia Soria, Ana Isabel de Ávila, Isabel Gallego, et al. (+15)
13 [GO] 2022―Dec―15 Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19 Elizabeth E. Zumbrun, Chengzi I. Kaku, Lukas Dillinger, Samantha E. Zak, Ana I. Kuehne, Russel R. Bakken, et al. (+11)
14 [GO] 2022―Dec―14 A Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Study To Evaluate the Efficacy and Safety of Camostat Mesylate (DWJ1248) in Adult Patients with Mild to Moderate COVID-19 Yeon-Sook Kim, Seng-Ho Jeon, Junghee Kim, Jong Hoon Koh, Seung Won Ra, Ji Won Kim, et al. (+28)
15 [GO] 2022―Nov―14 Lancemaside A from Codonopsis lanceolata: Studies on Antiviral Activity and Mechanism of Action against SARS-CoV-2 and Its Variants of Concern Tai Young Kim, Sangeun Jeon, Meehyun Ko, Young Eun Du, So-Ri Son, Dae Sik Jang, et al. (+2)
16 [GO] 2022―Oct―26 Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis Tilman Lingscheid, Martina Kinzig, Anne Krüger, Nils Müller, Georg Bölke, Pinkus Tober-Lau, et al. (+6)
17 [GO] 2022―Sep―13 A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part Hiroshi Mukae, Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi, Takumi Imamura, Takuhiro Sonoyama, et al. (+7)
18 [GO] 2022―Sep―12 Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults Ryosuke Shimizu, Takuhiro Sonoyama, Takahiro Fukuhara, Aya Kuwata, Yumiko Matsuo, Ryuji Kubota
19 [GO] 2022―Jul―12 New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19 Robert L. Atmar, Natalie Finch
20 [GO] 2022―Jul―05 Selection of Bis-Indolyl Pyridines and Triphenylamines as New Inhibitors of SARS-CoV-2 Cellular Entry by Modulating the Spike Protein/ACE2 Interfaces Delphine Lapaillerie, Cathy Charlier, Véronique Guyonnet-Dupérat, Emilie Murigneux, Henrique S. Fernandes, Fábio G. Martins, et al. (+19)
21 [GO] 2022―Jun―23 Characterizing SARS-CoV-2 Viral Clearance Kinetics to Improve the Design of Antiviral Pharmacometric Studies James A. Watson, Stephen M. Kissler, Nicholas P. J. Day, Yonatan H. Grad, Nicholas J. White
22 [GO] 2022―Jun―16 In Vitro Selection of Remdesivir-Resistant SARS-CoV-2 Demonstrates High Barrier to Resistance Liva Checkmahomed, Julie Carbonneau, Venice Du Pont, Nicholas C. Riola, Jason K. Perry, Jiani Li, et al. (+5)
23 [GO] 2022―Jun―15 Dual Inhibition of Vacuolar-ATPase and TMPRSS2 Is Required for Complete Blockade of SARS-CoV-2 Entry into Cells Simoun Icho, Edurne Rujas, Krithika Muthuraman, John Tam, Huazhu Liang, Shelby Landreth, et al. (+4)
24 [GO] 2022―Jun―01 Population Pharmacokinetics of Remdesivir and GS-441524 in Hospitalized COVID-19 Patients E. Leegwater, D. J. A. R. Moes, L. B. E. Bosma, T. H. Ottens, I. M. van der Meer, C. van Nieuwkoop, E. B. Wilms
25 [GO] 2022―May―09 Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants Jared Pitts, Jiani Li, Jason K. Perry, Venice Du Pont, Nicholas Riola, Lauren Rodriguez, et al. (+12)
26 [GO] 2022―Feb―22 Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody JS016 in Hospitalized Chinese Patients with COVID-19: A Phase 2/3, Multicenter, Randomized, Open-label, Controlled Trial Run Dong, Li Jiang, Ting Yang, Changsong Wang, Yi Zhang, Xu Chen, et al. (+7)
27 [GO] 2022―Feb―22 Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody JS016 in Hospitalized Chinese Patients with COVID-19: a Phase 2/3, Multicenter, Randomized, Open-Label, Controlled Trial Run Dong, Li Jiang, Ting Yang, Changsong Wang, Yi Zhang, Xu Chen, et al. (+7)
28 [GO] 2022―Jan―03 Reply to Casalini et al., “Bacterial Coinfections in COVID-19 Patients without a Positive Microbiologic Result: a Word of Caution” Jonathan Baghdadi, Sarah Bejo, Anthony Harris
29 [GO] 2022―Jan―03 Bacterial Coinfections in COVID-19 Patients without a Positive Microbiologic Result: a Word of Caution Giacomo Casalini, Giacomo Pozza, Andrea Giacomelli, Spinello Antinori
30 [GO] 2021―Dec―13 Early Use of Sarilumab in Patients Hospitalised with COVID-19 Pneumonia and Features of Systemic Inflammation. Nicolás Merchante, Sheila Cárcel, José Carlos Garrido-Gracia, Marta Trigo-Rodríguez, María Ángeles Esteban Moreno, Rafael León-López, et al. (+14)
31 [GO] 2021―Dec―13 Early Use of Sarilumab in Patients Hospitalized with COVID-19 Pneumonia and Features of Systemic Inflammation: the SARICOR Randomized Clinical Trial Nicolás Merchante, Sheila Cárcel, José Carlos Garrido-Gracia, Marta Trigo-Rodríguez, María Ángeles Esteban Moreno, Rafael León-López, et al. (+14)
32 [GO] 2021―Nov―22 A photoactivable natural product with broad antiviral activity against enveloped viruses including highly pathogenic coronaviruses Thomas Meunier, Lowiese Desmarets, Simon Bordage, Moussa Bamba, Kévin Hervouet, Yves Rouillé, et al. (+10)
33 [GO] 2021―Oct―11 MOXIDECTIN AND IVERMECTIN INHIBIT SARS-COV-2 REPLICATION IN VERO E6 CELLS BUT NOT IN HUMAN PRIMARY AIRWAY EPITHELIUM CELLS Nilima Dinesh Kumar, Bram M. ter Ellen, Ellen M. Bouma, Berit Troost, Denise P. I. van de Pol, Heidi H. van der Ende-Metselaar, et al. (+8)
34 [GO] 2021―Sep―20 The natural stilbenoid (-)-hopeaphenol inhibits cellular entry of SARS-CoV-2 USA-WA1/2020, B.1.1.7 and B.1.351 variants Ian Tietjen, Joel Cassel, Emery T. Register, Xiang Yang Zhou, Troy E. Messick, Frederick Keeney, et al. (+8)
35 [GO] 2021―Sep―07 Antibiotic Use and Bacterial Infection Among Inpatients in the First Wave of COVID-19: A Retrospective Cohort Study of 64,691 Patients Jonathan D. Baghdadi, KC Coffey, Timileyin Adediran, Katherine E. Goodman, Lisa Pineles, Larry S. Magder, et al. (+5)
36 [GO] 2021―Sep―07 Safety, tolerability, pharmacokinetics and immunogenicity of a monoclonal antibody (SCTA01) targeting SARS-CoV-2 in healthy adults: A randomized, double-blind, placebo-controlled, phase I study Yinjuan Li, Lu Qi, Haihong Bai, Chunyun Sun, Shuping Xu, Yu Wang, et al. (+14)
37 [GO] 2021―Aug―02 Candida auris Invasive Infections During a COVID-19 Case Surge Blake M. Hanson, An Q. Dinh, Truc T. Tran, Sebastian Arenas, Darryl Pronty, Hayley B. Gershengorn, et al. (+3)
38 [GO] 2021―Jul―12 Why Remdesivir Failed: Preclinical Assumptions Overestimate the Clinical Efficacy of Remdesivir for COVID-19 and Ebola Victoria C. Yan, Florian L. Muller
39 [GO] 2021―Jun―28 Pharmacokinetics and safety of XAV-19, a swine glyco-humanized polyclonal anti-SARS-CoV-2 antibody, for COVID-19-related moderate pneumonia: a randomized, double-blind, placebo-controlled, phase IIa study Benjamin Gaborit, Eric Dailly, Bernard Vanhove, Régis Josien, Karine Lacombe, Vincent Dubee, et al. (+13)
40 [GO] 2021―Jun―17 Erratum for Lu et al., “Development of a Simple In Vitro Assay To Identify and Evaluate Nucleotide Analogs against SARS-CoV-2 RNA-Dependent RNA Polymerase” Gaofei Lu, Xi Zhang, Weinan Zheng, Jialei Sun, Lan Hua, Lan Xu, et al. (+3)
41 [GO] 2021―Jun―13 Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 in Vitro Karen A. Gammeltoft, Yuyong Zhou, Carlos R. Duarte Hernandez, Andrea Galli, Anna Offersgaard, Rui Costa, et al. (+7)
42 [GO] 2021―May―17 Nodosome inhibition as a novel broad-spectrum antiviral strategy against arboviruses, enteroviruses and SARS-CoV-2 Daniel Limonta, Lovely Dyna-Dagman, William Branton, Valeria Mancinelli, Tadashi Makio, Richard W. Wozniak, et al. (+2)
43 [GO] 2021―May―11 Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab in Chinese Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled, First-In-Human Phase 1 Study Xiaojie Wu, Nanyang Li, Guoqin Wang, Wei Liu, Jicheng Yu, Guoying Cao, et al. (+15)
44 [GO] 2021―Apr―28 Luminore CopperTouch™ surface coating effectively inactivates SARS-CoV-2, Ebola and Marburg in vitro Emily K. Mantlo, Slobodan Paessler, Alexey Seregin, Alfred Mitchell
45 [GO] 2021―Apr―28 Overcoming culture restriction for SARS-CoV-2 in human cells facilitates the screening of compounds inhibiting viral replication Santseharay Ramirez, Carlota Fernandez-Antunez, Andrea Galli, Alexander Underwood, Long V. Pham, Line A. Ryberg, et al. (+10)
46 [GO] 2021―Mar―03 Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2 Wendy P. Painter, Wayne Holman, Jim A. Bush, Firas Almazedi, Hamzah Malik, Nicola C. J. E. Eraut, et al. (+3)
47 [GO] 2021―Mar―03 The anti-influenza virus drug favipiravir has little effect on replication of SARS-CoV-2 in cultured cells Yuriko Tomita, Makoto Takeda, Shutoku Matsuyama
48 [GO] 2021―Feb―09 Considering personalized Interferon-β therapy for COVID-19 Karim Dorgham, Avidan U. Neumann, Maxens Decavele, Charles-Edouard Luyt, Hans Yssel, Guy Gorochov
49 [GO] 2021―Feb―09 Plitidepsin: a repurposed drug for the treatment of COVID-19 Miguel Angel Martinez
50 [GO] 2021―Feb―09 AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19 Steven S. Good, Jonna Westover, Kie Hoon Jung, Xiao-Jian Zhou, Adel Moussa, Paolo La Colla, et al. (+3)
51 [GO] 2021―Feb―09 Reply to letter “Considering personalized Interferon-β therapy for COVID-19” Effat Davoudi-Monfared, Hossein Khalili
52 [GO] 2021―Feb―09 Remdesivir for COVID-19: Why Not Dose Higher? Victoria C. Yan, Florian L. Muller
53 [GO] 2021―Jan―29 Kinetic characterization and inhibitor screening for the proteases leading to identification of drugs against SARS-CoV-2 Chih-Jung Kuo, Tai-Ling Chao, Han-Chieh Kao, Ya-Min Tsai, Yi-Kai Liu, Lily Hui-Ching Wang, et al. (+3)
54 [GO] 2021―Jan―27 Limited Utility of Procalcitonin in Identifying Community-Associated Bacterial Infections in Patients Presenting with Coronavirus Disease 2019 Michael May, Michelle Chang, Donald Dietz, Sherif Shoucri, Justin Laracy, Magdalena E. Sobieszczyk, et al. (+3)
55 [GO] 2020―Dec―08 Favipiravir and the Need for Early Ambulatory Treatment of COVID-19 Tony M. Korman
56 [GO] 2020―Dec―08 Evidence-Based Guidelines Should Be Used to Inform COVID-19 Management Thomas L. Holland
57 [GO] 2020―Nov―03 New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19 Muneerah M. Aleissa, Emily A. Silverman, Luisa M. Paredes Acosta, Cameron T. Nutt, Aaron G. Richterman, Francisco M. Marty
58 [GO] 2020―Oct―30 Repurposing Nucleoside Analogs for Human Coronaviruses Keivan Zandi, Franck Amblard, Katie Musall, Jessica Downs-Bowen, Ruby Kleinbard, Adrian Oo, et al. (+7)
59 [GO] 2020―Oct―29 Development of a simple in vitro assay to identify and evaluate nucleotide analogs against SARS-CoV-2 RNA-dependent RNA polymerase Gaofei Lu, Xi Zhang, Weinan Zheng, Jialei Sun, Lan Hua, Lan Xu, et al. (+3)
60 [GO] 2020―Sep―23 Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV2 Infection (COVID-19) Peter A. McCullough
61 [GO] 2020―Sep―22 A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19 Yohei Doi, Masaya Hibino, Ryota Hase, Michiko Yamamoto, Yu Kasamatsu, Masahiro Hirose, et al. (+39)
62 [GO] 2020―Sep―01 Removal of remdesivir's metabolite GS-441524 by hemodialysis in a double lung transplant recipient with COVID-19 Minh Patrick Lê, Quentin Le Hingrat, Pierre Jaquet, Paul-Henri Wicky, Vincent Bunel, Laurent Massias, et al. (+6)
63 [GO] 2020―Aug―20 Antibiotic consumption and stewardship at a hospital outside of an early Coronavirus disease 2019 epicentre Deanna J. Buehrle, Brooke K. Decker, Marilyn M. Wagener, Amesh Adalja, Nina Singh, Mary C. McEllistrem, et al. (+2)
64 [GO] 2020―Aug―06 Atazanavir, alone or in combination with ritonavir, inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production Natalia Fintelman-Rodrigues, Carolina Q. Sacramento, Carlyle Ribeiro Lima, Franklin Souza da Silva, André C. Ferreira, Mayara Mattos, et al. (+12)
65 [GO] 2020―Jul―16 Discovery of M Protease inhibitors encoded by SARS-CoV-2 Hui-Chen Hung, Yi-Yu Ke, Sheng Yu Huang, Peng-Nien Huang, Yu-An Kung, Teng-Yuan Chang, et al. (+13)
66 [GO] 2020―Jul―14 Efficacy and safety of interferon β-1a in treatment of severe COVID-19: A randomized clinical trial Effat Davoudi-Monfared, Hamid Rahmani, Hossein Khalili, Mahboubeh Hajiabdolbaghi, Mohamadreza Salehi, Ladan Abbasian, et al. (+2)
67 [GO] 2020―Jul―09 Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations Catia Marzolini, Felix Stader, Marcel Stoeckle, Fabian Franzeck, Adrian Egli, Stefano Bassetti, et al. (+12)
68 [GO] 2020―Jul―03 Clinical trials of repurposed antivirals for SARS-CoV-2 Miguel Angel Martinez
69 [GO] 2020―Jun―23 IMPACT OF GLUCOCORTICOID TREATMENT IN SARS-COV-2 INFECTION MORTALITY: A RETROSPECTIVE CONTROLLED COHORT STUDY Ana Fernández Cruz, Belén Ruiz-Antorán, Ana Muñoz Gómez, Aránzazu Sancho López, Patricia Mills Sánchez, Gustavo Adolfo Centeno Soto, et al. (+13)
70 [GO] 2020―Jun―08 The good, the bad & the hoax: when publication instantaneously impacts treatment strategies for COVID-19 François Danion, Yvon Ruch, Marion Fourtage, Charlotte Kaeuffer, Valentin Greigert, Nicolas Lefebvre, et al. (+3)
71 [GO] 2020―Jun―08 Suramin inhibits SARS-CoV-2 infection in cell culture by interfering with early steps of the replication cycle Clarisse Salgado Benvindo da Silva, Melissa Thaler, Ali Tas, Natacha S. Ogando, Peter J. Bredenbeek, Dennis K. Ninaber, et al. (+4)
72 [GO] 2020―May―14 Accelerating drug development through repurposed FDA approved drugs for COVID-19: speed is important, not haste James T. Gordy, Kaushiki Mazumdar, Noton K. Dutta
73 [GO] 2020―May―06 Inhibition of SARS-CoV-2 infection by the cyclophilin inhibitor Alisporivir (Debio 025) Laurent Softic, Rozenn Brillet, François Berry, Nazim Ahnou, Quentin Nevers, Margot Morin-Dewaele, et al. (+5)
74 [GO] 2020―May―05 Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs Sangeun Jeon, Meehyun Ko, Jihye Lee, Inhee Choi, Soo Young Byun, Soonju Park, et al. (+2)
75 [GO] 2020―Apr―21 Nafamostat mesylate blocks activation of SARS-CoV-2: New treatment option for COVID-19 Markus Hoffmann, Simon Schroeder, Hannah Kleine-Weber, Marcel A. Müller, Christian Drosten, Stefan Pöhlmann
76 [GO] 2020―Mar―19 Updated approaches against SARS-CoV-2 Haiou Li, Yunjiao Zhou, Meng Zhang, Haizhou Wang, Qiu Zhao, Jing Liu
77 [GO] 2020―Mar―06 Compounds with therapeutic potential against novel respiratory 2019 coronavirus Miguel Angel Martinez
 [1] 

77 Results       Page 1


[de][en]

Last change 2023―Oct―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.004 sec